PL3725803T3 - Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania - Google Patents

Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania

Info

Publication number
PL3725803T3
PL3725803T3 PL20165165T PL20165165T PL3725803T3 PL 3725803 T3 PL3725803 T3 PL 3725803T3 PL 20165165 T PL20165165 T PL 20165165T PL 20165165 T PL20165165 T PL 20165165T PL 3725803 T3 PL3725803 T3 PL 3725803T3
Authority
PL
Poland
Prior art keywords
binding molecules
complement factor
human complement
bind human
bind
Prior art date
Application number
PL20165165T
Other languages
English (en)
Polish (pl)
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Louis Boon
Petrus Johannes Simons
Original Assignee
Broteio Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B.V. filed Critical Broteio Pharma B.V.
Publication of PL3725803T3 publication Critical patent/PL3725803T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL20165165T 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania PL3725803T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof
EP14729463.1A EP2999714B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof
EP20165165.0A EP3725803B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2b and uses thereof

Publications (1)

Publication Number Publication Date
PL3725803T3 true PL3725803T3 (pl) 2022-04-04

Family

ID=48485015

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20165165T PL3725803T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Country Status (14)

Country Link
US (2) US9944717B2 (https=)
EP (2) EP2999714B1 (https=)
JP (3) JP2016520313A (https=)
CN (1) CN105492461B (https=)
AU (1) AU2014269193C1 (https=)
CA (1) CA2913318C (https=)
DK (2) DK3725803T3 (https=)
ES (2) ES2904709T3 (https=)
HU (2) HUE049769T2 (https=)
LT (2) LT2999714T (https=)
MX (1) MX366046B (https=)
PL (2) PL3725803T3 (https=)
PT (2) PT3725803T (https=)
WO (1) WO2014189378A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CN105492461B (zh) * 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用
HUE073475T2 (hu) * 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
WO2021026609A1 (en) * 2019-08-12 2021-02-18 CSL Innovation Pty Ltd Complement c2 binding proteins and uses thereof
AU2023210793A1 (en) * 2022-01-29 2024-06-06 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
CN105492461B (zh) 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Also Published As

Publication number Publication date
JP2020007318A (ja) 2020-01-16
ES2904709T3 (es) 2022-04-05
LT2999714T (lt) 2020-07-10
HUE049769T2 (hu) 2020-10-28
US10717785B2 (en) 2020-07-21
AU2014269193C1 (en) 2020-02-20
US9944717B2 (en) 2018-04-17
DK2999714T3 (da) 2020-06-02
PL2999714T3 (pl) 2020-10-19
EP2999714B1 (en) 2020-04-01
US20180319895A1 (en) 2018-11-08
MX2015016120A (es) 2016-10-28
CN105492461A (zh) 2016-04-13
HUE057858T2 (hu) 2022-06-28
PT3725803T (pt) 2021-12-24
MX366046B (es) 2019-06-26
JP7414929B2 (ja) 2024-01-16
LT3725803T (lt) 2022-03-10
JP2016520313A (ja) 2016-07-14
CA2913318A1 (en) 2014-11-27
EP3725803A1 (en) 2020-10-21
AU2014269193A1 (en) 2015-12-17
JP2023002684A (ja) 2023-01-10
WO2014189378A1 (en) 2014-11-27
CA2913318C (en) 2024-03-26
AU2014269193B2 (en) 2019-08-15
ES2784616T3 (es) 2020-09-29
PT2999714T (pt) 2020-04-30
HK1223385A1 (zh) 2017-07-28
US20160108134A1 (en) 2016-04-21
EP3725803B1 (en) 2021-12-15
EP2999714A1 (en) 2016-03-30
CN105492461B (zh) 2019-11-26
DK3725803T3 (da) 2022-03-07
JP7163254B2 (ja) 2022-10-31

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
ZA201505209B (en) Binding molecules for bcma and cd3
IL254223A (en) CD20 binding compounds and their uses
HUE057858T2 (hu) Humán komplement faktor C2B-t megkötõ kötõ molekulák és alkalmazásaik
IL240045A0 (en) Antigen-binding molecules activate bi-specific t cells
SG11201505762XA (en) Il-11r binding proteins and uses thereof
ZA201803841B (en) Binding molecules specific for asct2 and uses thereof
IL236617A0 (en) rspo3 binding factors and their uses
ZA201506186B (en) Ligand binding molecules and uses thereof
SI3072905T1 (sl) IL-17A-vezavno sredstvo in uporabe le-tega
IL237845A0 (en) New 17a–il binding molecules and their medical uses
GB201306588D0 (en) Peptides and Binding Partners Therefor
ZA201503962B (en) Fines binding process and binding composition thereof
HU4488U (en) Plaster-coated and edge-protected chipboard